Table 2.

Genotype frequencies and OR estimates for breast cancer risk

Cases (n = 402) n (%)Controls (n = 402) n (%)PaORMultivariate adjusted ORb
XRCC3-T241M
    T/T139 (34.6)146 (36.3)0.101.001.00
    T/M186 (46.3)200 (49.8)0.98 (0.72–1.33)0.96 (0.71–1.32)
    M/M77 (19.2)56 (13.9)1.44 (0.95–2.19)1.44 (0.94–2.19)
    T/T + T/M325 (80.9)346 (86.1)0.051.001.00
    M/M77 (19.2)56 (13.9)1.46 (1.02–2.13)1.47 (1.00–2.15)
XRCC1-R399Q
    R/R168 (41.8)160 (39.8)0.851.001.00
    R/Q179 (44.5)185 (46.0)0.92 (0.68–1.24)0.91 (0.67–1.23)
    Q/Q55 (13.7)57 (14.2)0.92 (0.60–1.41)0.88 (0.57–1.37)
    R/R + R/Q347 (86.3)345 (85.8)0.841.001.00
    Q/Q55 (13.7)57 (14.2)0.96 (0.64–1.43)0.93 (0.62–1.40)
  • a χ2 test for homogeneity of proportions in contingency table.

  • b Adjusted for ethnicity (Caucasian or Caucasian and other ethnic group), age (years), and FH of breast cancer (at least one first-degree relative).